文献速递消化道肿瘤与早癌消化内镜

亚太近端结肠肿瘤风险评分的开发与验证

Development and Validation of the Asia-Pacific Proximal Colon Neoplasia Risk Score.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-01-07

研究基于亚洲14个中心7954例无症状受试者的结肠镜筛查数据,随机分为开发队列(5303例)和验证队列(2651例),开发并验证了一个0-15分的近端进展期肿瘤(APN)风险评分。验证队列中高危组(≥4分)APN患病率为9.4%,平均风险组为1.9%(调整相对风险5.08,95%CI 3.38-7.62,P<.001),评分c-statistic为0.74。结论推荐乙状结肠镜筛查评分≥4分者应接受结肠镜检查。

要点

  • 评分≥4分定义为高危,验证队列中高危组APN患病率9.4%。
  • 评分包含年龄、吸烟、结直肠癌家族史和远端结直肠肿瘤。
  • 高危者需转诊结肠镜,需转诊人数为11(95%CI 10-13)。

核心结论

  • 开发并验证了一个识别近端进展期肿瘤(APN)风险的评分系统,乙状结肠镜筛查评分≥4分者应接受结肠镜评估。

研究设计与样本

  • 研究收集了亚洲14个中心7954例接受结肠镜筛查的无症状受试者(年龄50-75岁)数据。
  • 随机分配5303例至开发队列,2651例至验证队列。
  • 收集年龄、性别、结直肠癌家族史、吸烟、饮酒、体重指数、疾病史及非甾体抗炎药或阿司匹林使用等数据。

主要发现

  • 验证队列中79.5%为平均风险,20.5%为高风险。
  • 平均风险组APN患病率为1.9%,高风险组为9.4%(调整相对风险5.08;95%CI 3.38-7.62;P<.001)。
  • 评分c-statistic为0.74(95%CI 0.68-0.79),仅远端发现为0.67(95%CI 0.60-0.74)。
  • Hosmer-Lemeshow拟合优度检验统计量大于0.05,表明验证集可靠性。
  • 需转诊人数为11(95%CI 10-13),需筛查人数为15(95%CI 12-17)。

关键数值与推荐

  • 评分范围0-15分,0-3分为平均风险,4分及以上为高风险。
  • 评分项目:年龄61-70岁计3分,≥70岁计4分;当前或既往吸烟计2分;一级亲属结直肠癌家族史计2分;远端结直肠非进展期腺瘤5-9mm计2分,进展期肿瘤计7分。

临床怎么用

  • 对接受乙状结肠镜筛查的无症状人群应用该评分,评分≥4分者建议转诊结肠镜检查。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Patients found to be at high risk of advanced proximal neoplasia (APN) after flexible sigmoidoscopy screening should be considered for colonoscopy examination. We developed and validated a scoring system to identify persons at risk for APN. METHODS: We collected data from 7954 asymptomatic subjects (age, 50-75 y) who received screening colonoscopy examinations at 14 sites in Asia. We randomly assigned 5303 subjects to the derivation cohort and the remaining 2651 to the validation cohort. We collected data from the derivation cohort on age, sex, family history of colorectal cancer, smoking, drinking, body mass index, medical conditions, and use of nonsteroidal anti-inflammatory drugs or aspirin. Associations between the colonoscopic findings of APN and each risk factor were examined using the Pearson χ2 test, and we assigned each participant a risk score (0-15), with scores of 0 to 3 as average risk and scores of 4 or higher as high risk. The scoring system was tested in the validation cohort. We used the Cochran-Armitage test of trend to compare the prevalence of APN among subjects in each group. RESULTS: In the validation cohort, 79.5% of patients were classified as average risk and 20.5% were classified as high risk. The prevalence of APN in the average-risk group was 1.9% and in the high-risk group was 9.4% (adjusted relative risk, 5.08; 95% CI, 3.38-7.62; P < .001). The score included age (61-70 y, 3; ≥70 y, 4), smoking habits (current/past, 2), family history of colorectal cancer (present in a first-degree relative, 2), and the presence of neoplasia in the distal colorectum (nonadvanced adenoma 5-9 mm, 2; advanced neoplasia, 7). The c-statistic of the score was 0.74 (95% CI, 0.68-0.79), and for distal findings alone was 0.67 (95% CI, 0.60-0.74). The Hosmer-Lemeshow goodness-of-fit test statistic was greater than 0.05, indicating the reliability of the validation set. The number needed to refer was 11 (95% CI, 10-13), and the number needed to screen was 15 (95% CI, 12-17). CONCLUSIONS: We developed and validated a scoring system to identify persons at risk for APN. Screening participants who undergo flexible sigmoidoscopy screening with a score of 4 points or higher should undergo colonoscopy evaluation.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Wong MCS, Rerknimitr R, Lee Goh K, et al. Development and Validation of the Asia-Pacific Proximal Colon Neoplasia Risk Score. Clin Gastroenterol Hepatol. 2020. PMID: 31923642. doi:10.1016/j.cgh.2019.12.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。